{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:09:54Z","timestamp":1792537794031,"version":"4.5.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jaut.2020.102425","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T17:25:02Z","timestamp":1583256302000},"page":"102425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Insights into the treatment of rheumatoid arthritis: A paradigm in medicine"],"prefix":"10.1016","volume":"110","author":[{"given":"Josef S.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib1","first-page":"219","article-title":"Consideration of pathogenesis of rheumatoid arthritis as collagen autoimmunity","volume":"139","author":"Steffen","year":"1970","journal-title":"Z. Immunitatsforsch. Allerg. Klin. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102425_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/art.1780230405","article-title":"Lymphocyte transformation to denatured type I collagen and B lymphocyte alloantigens in rheumatoid arthritis","volume":"23","author":"Smolen","year":"1980","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2020.102425_bib3","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1172\/JCI110416","article-title":"Responder cells in the human autologous mixed lymphocyte reaction","volume":"68","author":"Smolen","year":"1981","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jaut.2020.102425_bib4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1172\/JCI110637","article-title":"Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture","volume":"70","author":"Luger","year":"1982","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jaut.2020.102425_bib5","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.4049\/jimmunol.124.4.1883","article-title":"T cell requirements for generation of helper factor(s) in man: analysis of the subsets involved","volume":"124","author":"Reinherz","year":"1980","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102425_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00000441-198504000-00003","article-title":"Systemic lupus erythematosus: delineation of subpopulations by clinical, serologic, and T cell subset analysis","volume":"289","author":"Smolen","year":"1985","journal-title":"Am. J. Med. Sci."},{"issue":"5","key":"10.1016\/j.jaut.2020.102425_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0002-9343(82)90544-7","article-title":"Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features","volume":"72","author":"Smolen","year":"1982","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.jaut.2020.102425_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jaut.2020.102425_bib9","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1172\/JCI111896","volume":"75","author":"Smolen","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2020.102425_bib10","first-page":"153","article-title":"The magnitude of the autologous mixed lymphocyte reaction itself is regulated","volume":"72","author":"Steinberg","year":"1983","journal-title":"Behring Inst. Mitt."},{"key":"10.1016\/j.jaut.2020.102425_bib11","first-page":"135","article-title":"Responder cells in the human autologous mixed lymphocyte reaction (AMLR). Characterization and interactions in healthy individuals and patients with systemic lupus erythematosus","volume":"72","author":"Smolen","year":"1983","journal-title":"Behring Inst. Mitt."},{"issue":"5","key":"10.1016\/j.jaut.2020.102425_bib12","first-page":"549","volume":"10","author":"Bencivelli","year":"1992","journal-title":"Clin. Exp. Rheumatol."},{"issue":"12","key":"10.1016\/j.jaut.2020.102425_bib13","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/anr.1780321204","article-title":"Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis","volume":"32","author":"Hassfeld","year":"1989","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1172\/JCI115921","article-title":"Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex","volume":"90","author":"Steiner","year":"1992","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1172\/JCI119504","volume":"100","author":"Skriner","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2020.102425_bib16","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/ard.2005.035691","article-title":"Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis","volume":"64","author":"Nell","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2020.102425_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/35.11.1067","article-title":"Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus","volume":"35","author":"Studnicka-Benke","year":"1996","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.jaut.2020.102425_bib18","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2020.102425_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/rheumatology\/38.3.202","article-title":"Cytokine production by synovial T cells in rheumatoid arthritis","volume":"38","author":"Steiner","year":"1999","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl","key":"10.1016\/j.jaut.2020.102425_bib20","first-page":"13","article-title":"Early arthritis therapy: rationale and current approach","volume":"25","author":"Machold","year":"1998","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.jaut.2020.102425_bib21","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"2","author":"Brennan","year":"1989","journal-title":"Lancet"},{"issue":"8930","key":"10.1016\/j.jaut.2020.102425_bib23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jaut.2020.102425_bib24","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib25","first-page":"37","article-title":"Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade","volume":"112","author":"Wagner","year":"2003","journal-title":"Dev Biol (Basel)"},{"issue":"22","key":"10.1016\/j.jaut.2020.102425_bib26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102425_bib27","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"9227","key":"10.1016\/j.jaut.2020.102425_bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaut.2020.102425_bib29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"16","key":"10.1016\/j.jaut.2020.102425_bib30","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1073\/pnas.82.16.5490","article-title":"Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2)","volume":"82","author":"Hirano","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6092","key":"10.1016\/j.jaut.2020.102425_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"issue":"4867","key":"10.1016\/j.jaut.2020.102425_bib32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.3136546","article-title":"Cloning and expression of the human interleukin-6 (BSF-2\/IFN beta 2) receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2020.102425_bib33","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1136\/ard.59.suppl_1.i21","article-title":"Anti-interleukin 6 receptor antibody treatment in rheumatic disease","volume":"59","author":"Nishimoto","year":"2000","journal-title":"Ann. Rheum. Dis."},{"issue":"8542","key":"10.1016\/j.jaut.2020.102425_bib34","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0140-6736(87)91672-2","article-title":"Long-term outcome of treating rheumatoid arthritis: results after 20 years","volume":"1","author":"Scott","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2020.102425_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/rheumatology\/25.1.44","article-title":"Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression","volume":"25","author":"Dawes","year":"1986","journal-title":"Br. J. Rheumatol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102425_bib36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/ard.45.11.945","article-title":"Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy","volume":"45","author":"Dawes","year":"1986","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2020.102425_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients","volume":"31","author":"Van der Heijde","year":"1992","journal-title":"Br. J. Rheumatol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102425_bib38","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jbmr.5650040116","article-title":"Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro","volume":"4","author":"Pfeilschifter","year":"1989","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jaut.2020.102425_bib40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/art.1780270902","article-title":"Chondroclasts and osteoclats at subchondral sites of erosion in the rheumatoid joint","volume":"27","author":"Bromley","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib41","first-page":"510","article-title":"Die allgemeine chirurgische Pathologie und Therapie","author":"Billroth","year":"1876"},{"issue":"5","key":"10.1016\/j.jaut.2020.102425_bib42","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0002-9440(10)64289-7","article-title":"Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis","volume":"162","author":"Seemayer","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.jaut.2020.102425_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-0773.1997.tb01971.x","article-title":"Comparative study on the effect of calcium channel blockers on basal and parathyroid hormone-induced bone resorption in vitro","volume":"80","author":"Redlich","year":"1997","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.jaut.2020.102425_bib44","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J."},{"issue":"5184","key":"10.1016\/j.jaut.2020.102425_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1126\/science.7939685","article-title":"c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling","volume":"266","author":"Grigoriadis","year":"1994","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.jaut.2020.102425_bib46","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI0215582","article-title":"Osteoclasts are essential for TNF-alpha-mediated joint destruction","volume":"110","author":"Redlich","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.jaut.2020.102425_bib47","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","article-title":"TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis","volume":"159","author":"Pettit","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2020.102425_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/art.22313","article-title":"Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis","volume":"56","author":"Hayer","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/art.20947","article-title":"Magnetic resonance imaging evidence of tendinopathy in early rheumatoid arthritis predicts tendon rupture at six years","volume":"52","author":"McQueen","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib50","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/ard.2008.094128","article-title":"Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib51","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib52","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/ar2418","article-title":"The need for prognosticators in rheumatoid arthritis. Biological and clinical markers - where are we now?","volume":"10","author":"Smolen","year":"2008","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib53","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.37797","article-title":"Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis","volume":"65","author":"Binder","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001096","article-title":"Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis","volume":"6","author":"Smolen","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib56","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","article-title":"Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its antiinflammatory effects: disassociation of the link between inflammation and destruction","volume":"71","author":"Smolen","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2012-201970","article-title":"Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients","volume":"72","author":"Aletaha","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"10055","key":"10.1016\/j.jaut.2020.102425_bib58","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget personalised medicine and focus on abating disease activity","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"7","key":"10.1016\/j.jaut.2020.102425_bib61","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jaut.2020.102425_bib62","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib63","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jaut.2020.102425_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/ard.4.4.71","article-title":"Gold treatment in rheumatoid arthritis","volume":"4","author":"Fraser","year":"1945","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib65","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/rheumatology\/20.1.14","article-title":"The assessment of disease activity in rheumatoid arthritis using a multivariate analysis","volume":"20","author":"Mallya","year":"1981","journal-title":"Rheumatol. Rehabil."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199507203330301","article-title":"Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study group","volume":"333","author":"Tugwell","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2020.102425_bib67","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/art.1780330403","article-title":"Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group","volume":"33","author":"Paulus","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib68","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib69","first-page":"579","article-title":"Development of a Disease activity score based on judgement in clinical practice by rheumatologists","volume":"20","author":"Van der Heijde","year":"1993","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2020.102425_bib70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.51.2.177","article-title":"Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis","volume":"51","author":"van der Heijde","year":"1992","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib72","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.jaut.2020.102425_bib73","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","article-title":"The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses","volume":"41","author":"Aletaha","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2020.102425_bib74","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res."},{"key":"10.1016\/j.jaut.2020.102425_bib75","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","article-title":"How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?","volume":"74","author":"Fleischmann","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib76","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib77","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib78","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American college of rheumatology\/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216529","article-title":"Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR\/EULAR boolean criteria optimal?","author":"Studenic","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jaut.2020.102425_bib81","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.jaut.2020.102425_bib82","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/art.30634","article-title":"Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints","volume":"63","author":"Aletaha","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib83","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib84","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1136\/ard.2011.153734","article-title":"Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression","volume":"70","author":"Aletaha","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jaut.2020.102425_bib85","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/ard.2010.131201","article-title":"Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab","volume":"69","author":"Klarenbeek","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib86","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/ard.2004.034371","article-title":"Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib87","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib88","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-017-1346-5","article-title":"Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition","volume":"19","author":"Schoels","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl 3","key":"10.1016\/j.jaut.2020.102425_bib89","article-title":"Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2020.102425_bib90","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.jaut.2020.102425_bib91","first-page":"2162","article-title":"Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis","volume":"33","author":"Weisman","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2020.102425_bib92","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jaut.2020.102425_bib93","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","article-title":"Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets","volume":"15","author":"Aletaha","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2020.102425_bib94","article-title":"Guidance for Industry - rheumatoid arthritis: developing drug products for treatment","author":"Food and Drug Administration","year":"2013","journal-title":"Draft Gudance"},{"key":"10.1016\/j.jaut.2020.102425_bib95","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the Disease Activity Score 28 (DAS28) and EULAR response criteria based on CRP against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on ESR","volume":"68","author":"Wells","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.jaut.2020.102425_bib96","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.39996","article-title":"Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria","volume":"69","author":"Smolen","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib97","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib98","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F","article-title":"Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time","volume":"42","author":"Drossaers-Bakker","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib99","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/art.22052","article-title":"Measuring function in rheumatoid arthritis: identifying reversible and irreversible components","volume":"54","author":"Aletaha","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jaut.2020.102425_bib100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2007.071415","article-title":"Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results","volume":"67","author":"Aletaha","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2020.102425_bib101","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/ard.2009.114652","article-title":"Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib102","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","article-title":"The effects of structural damage on functional disability in psoriatic arthritis","volume":"76","author":"Kerschbaumer","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib103","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2009.118430","article-title":"Impact of comorbidity on physical function in patients with rheumatoid arthritis","volume":"69","author":"Radner","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 59","key":"10.1016\/j.jaut.2020.102425_bib104","first-page":"S18","article-title":"The assessment of disease activity in rheumatoid arthritis","volume":"28","author":"Smolen","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2020.102425_bib105","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/ard.2010.138693","article-title":"Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction","volume":"70","author":"Aletaha","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib106","series-title":"Primer on the Rheumatic Diseases","year":"1993"},{"key":"10.1016\/j.jaut.2020.102425_bib107","first-page":"1117","article-title":"Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians","volume":"17","author":"McCarty","year":"1990","journal-title":"J. Rheumatol."},{"issue":"Suppl 25","key":"10.1016\/j.jaut.2020.102425_bib108","first-page":"4","article-title":"Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis","volume":"17","author":"Wilske","year":"1990","journal-title":"J. Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2020.102425_bib109","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \"second-line\" antirheumatic drugs. A randomized, controlled trial","volume":"124","author":"van der Heide","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2020.102425_bib110","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9343(01)00872-5","article-title":"Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies","volume":"111","author":"Lard","year":"2001","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2020.102425_bib111","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2020.102425_bib112","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib113","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1002\/art.21410","article-title":"The need for new classification criteria for rheumatoid arthritis","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib114","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.10195","article-title":"Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. (Conference summary)","volume":"46","author":"Huizinga","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib115","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"The 2010 American college of rheumatology\/European league against rheumatism classification criteria for rheumatoid arthritis","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib116","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/annrheumdis-2013-203284","article-title":"Performance of the 2010 ACR\/EULAR classification criteria for rheumatoid arthritis: a systematic literature review","volume":"73","author":"Radner","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib117","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2020.102425_bib118","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib119","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)","volume":"73","author":"Nam","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2020.102425_bib120","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/ard.2010.141234","article-title":"The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib121","article-title":"Progression of rheumatoid arthritis joint damage in sustained clinical remission: effect of disease activity levels preceding the radiographic assessment","author":"Aletaha","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jaut.2020.102425_bib122","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102425_bib123","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2015","journal-title":"Arthritis Care Res (Hoboken )"},{"issue":"6","key":"10.1016\/j.jaut.2020.102425_bib125","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 11","key":"10.1016\/j.jaut.2020.102425_bib127","first-page":"S64","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken )"},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.berh.2018.08.004","article-title":"Disease activity assessment in patients with psoriatic arthritis","volume":"32","author":"Kerschbaumer","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2020.102425_bib129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clim.2016.07.019","article-title":"Implications of the diversity of class I HLA associations in psoriatic arthritis","volume":"172","author":"Winchester","year":"2016","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/annrheumdis-2011-200093","article-title":"Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set","volume":"71","author":"Fitzgerald","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2020.102425_bib131","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3899\/jrheum.180249","article-title":"Comparison of different remission and low disease definitions in psoriatic arthritis and evaluation of their prognostic value","volume":"46","author":"Coates","year":"2019","journal-title":"J. Rheumatol."},{"issue":"10136","key":"10.1016\/j.jaut.2020.102425_bib132","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaut.2020.102425_bib133","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","article-title":"Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression","volume":"76","author":"Aletaha","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2020.102425_bib134","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"suppl. 2","key":"10.1016\/j.jaut.2020.102425_bib135","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/annrheumdis-2017-eular.3762","article-title":"Outcomes associatded with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2020.102425_bib136","article-title":"Determinants of patient-reported psoriatic arthritis impact of disease: an analysis of the association with gender in 458 patients from 14 countries","author":"Orbai","year":"2019","journal-title":"Arthritis Care Res (Hoboken )"},{"issue":"12","key":"10.1016\/j.jaut.2020.102425_bib137","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1136\/annrheumdis-2015-208509","article-title":"The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?","volume":"74","author":"Helliwell","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jaut.2020.102425_bib138","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2015-208521","article-title":"Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates","volume":"74","author":"Schoels","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2020.102425_bib139","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2020.102425_bib140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib141","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"10012","key":"10.1016\/j.jaut.2020.102425_bib142","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaut.2020.102425_bib143","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.jaut.2020.102425_bib144","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120300366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120300366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:26:57Z","timestamp":1760257617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841120300366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":144,"alternative-id":["S0896841120300366"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102425","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into the treatment of rheumatoid arthritis: A paradigm in medicine","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102425"}}